Review
Copyright ©The Author(s) 2018.
World J Gastroenterol. Jun 21, 2018; 24(23): 2413-2426
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2413
Table 1 Gadolinium-based magnetic resonance imaging contrast agent
Contrast agentCategoryRelaxivityStructureConcentration(mmol/mL)Reccomended dosage (mmol/kg)
Gadoterate-meglumineECFAsStandardmacrocyclic0.50.1
GadobutrolECFAsStandardmacrocyclic1.00.1
GadoteridolECFAsStandardmacrocyclic0.50.1
Gadopentetate- dimeglumineECFAsStandardLinear0.50.1
GadoversetamideECFAsStandardLinear0.50.1
GadodiamideECFAsStandardLinear0.50.1
Gadofosfaset-trisodiumBPCAsHighLinear0.250.03
Gadobenate- dimeglumineHCAsHighLinear0.50.1
Gadoxetate-disodiumHCAsHighLinear0.250.025
Table 2 Magnetic resonance imaging perfusion with dynamic contrast-enhanced magnetic resonance imaging in the assessment of hepatocellular carcinoma, focus on diagnosis, characterization, response to therapy, and prognosis
Ref.YearMagnet (Tesla)Contrast agentParameters
Diagnosis and characterization
Taouli et al[38]20131.5 TGadobenate-dimeglumine and gadopentetate-dimeglumineAF, VF, ART, DV, MTT
Chen et al[39]20173 TGD-EOB-DTPAKtrans, Kep, iAUC, max-Ktrans
Jajamovich et al[40]20163 TGadobenate-dimeglumineART, K trans, ve, kep, τ
Abdullah et al[61]20081.5 TGadoterate-dimeglumineHPI, MTT, DV, TF, AF, PF
Response to therapy
Ippolito et al[41]20161.5 TGD-EOB-DTPAME, MRE, RAE, RE, RLE, RVE, TTP
Taouli et al[38]20131.5 TGadobenate-dimeglumine and Gadopentetate-dimeglumineAF, VF, ART, DV, MTT
Chen et al[45]20161.5 TGadodiamidePeak, Slope, AUC, Ktrans, Kep, Ve
Prognosis
Chen et al[45]20161.5 TGadodiamidePeak, Slope, AUC, Ktrans, Kep, Ve
Chen et al[45]20161.5 TGadodiamideART, AF, PF, TF, MTT, DV, PEAK, SLOPE, AUC